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pression and the immunoprofiles of the tumor suppressor 
genes, aneuploidy, proliferation, age, gender,   -fetoprotein 
levels, tumor size, tumor grade and underlying liver disease. 
 Conclusion: In 67% of the patients with HCC, sst2 could be 
detected in the tumor. No clinical, pathological or biological 
characteristics were specific for sst2-positive tumors. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is the most common 
primary liver cancer and fifth most common cancer in 
the world. Recent reports suggest an increase in the inci-
dence of HCC in the Western World; however, this may 
reflect a referral bias  [1, 2] . Only a minority of patients 
can be treated by partial liver resection, liver transplanta-
tion or local treatment (radiofrequency, percutaneous 
ethanol injection, transarterial chemoembolization). Be-
cause HCC is not sensitive to systemic chemotherapy  [3] , 
other therapies are tried. Results of studies investigating 
the effect of somatostatin analogues on HCC in humans 
are conflicting  [4–8] . Somatostatin receptors (SS-Rs) 
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 Abstract 
 Background/Aim: The evidence on the efficacy of soma-
tostatin analogues in the treatment of hepatocellular carci-
noma (HCC) in humans is conflicting. A variety of human tu-
mors demonstrate somatostatin receptors. All subtypes 
bind human somatostatin with high affinity, while soma-
tostatin analogues bind with high affinity to somatostatin 
receptor subtype 2 (sst2). We investigated the sst2 expres-
sion in HCC and examined whether HCCs expressing sst2 are 
a distinct subgroup.  Patients and Methods: Forty-five hu-
man HCCs were tested for sst2 expression and biological al-
terations. The proliferative capacity was determined with 
Ki67 immunostaining and the DNA ploidy status was mea-
sured by fluorescent in situ hybridization with a chromo-
some 1-specific repetitive DNA probe. Expression of tumor 
suppressor genes (p16, p53 and Rb1) was measured by im-
munohistochemistry.  Results: sst2 expression was detected 
in 30 tumors (67%). No correlation existed between sst2 ex-
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have been demonstrated in a variety of human tumors. 
At least 5 different human subtypes (SS-R subtype 1–5) 
have been cloned. All subtypes bind human somatostatin 
with high affinity, while somatostatin analogues bind 
with high affinity to SS-R subtype 2 (sst2). Literature data 
on the expression of SS-Rs in HCC are scarce. There is no 
study published, investigating whether HCC tumors ex-
pressing SS-Rs are a distinct subgroup at the genetic lev-
el. To investigate the SS-Rs in HCC and to test whether 
specific genetic alterations are associated with SS-Rs-
positive or SS-Rs-negative HCCs, we examined protein 
(over)expression of tumor suppressor genes (p16, p53 and 
Rb1) by immunohistochemistry. Further, the prolifera-
tive capacity was examined by immunostaining of Ki67 
and DNA ploidy status (aneuploidy) was measured by 
fluorescent in situ hybridization (FISH) with a chromo-
some 1-specific repetitive DNA probe. Our results will 
indicate the existence of SS-Rs in human HCC, and we 
will describe whether there is a correlation between SS-Rs 
expression and clinical and pathological characteristics, 
or alterations of investigated proto-oncogenes.
 Material and Methods 
 Patient Material 
 Tissue of surgically resected tumors of patients with HCC 
were analyzed in this study. The diagnosis was formulated ac-
cording to the guidelines issued by the World Health Organiza-
tion  [9] . We collected representative paraffin blocks from neo-
plastic liver cell specimens. HCCs were graded using a standard 
grading system  [10] .
 Tumor samples from surgical resections of 58 patients with 
HCC were selected for the tissue microarray (TMA). Of each re-
section specimen, 0.6-mm tissue cylinders were punched out of 
the tissue blocks, and brought into the array block with regular 
spacing between the cylindrical biopsies. From each patient, 2 tis-
sue cores were included in the TMA. A standard HE-stained his-
tological section of the TMA was made for quality control. In 10 
cases, no adequate carcinoma tissue cores were available for anal-
ysis due to absence or inadequate numbers of tumor cells. In 3 
cases, SS-Rs could not be determined by technical errors. A total 
of 90 liver tissue samples were available for analysis, i.e. 45 
HCCs.
 Fluorescent in situ Hybridization  
 FISH was performed on a 4-  m-thick tissue section of the 
TMA that was adhered to an aminoacetylsilane (AAS)-coated 
slide (Starfrost, Berlin, Germany). The (peri)centromeric DNA 
probe for chromosome 1 was labeled with Spectrum Green using 
a Nick Translation Reagent Kit (Vysis, Downers Grove, Ill., USA) 
according to the manufacturer’s directions. The FISH procedure 
was carried out basically as described before by us  [11, 12] . Brief-
ly, after appropriate pepsin digestion, sections were heat-dena-
tured for 2 min in 70% formamide in 2 ! SSC, and hybridized 
overnight at 37 ° C with the denatured probes in a hybridization 
mixture containing 2 ng/  l DNA probe, 500 ng/  l herring sperm 
DNA (Sigma, St. Louis Mo., USA), 0.1% Tween-20, 10% dextran 
sulphate, and 60% formamide in 2 ! SSC at pH 7.0. Then, a series 
of stringent washes followed to remove unbound probe. Finally, 
the section was counterstained with DAPI in antifade solution 
(Vectashield; Vector, Burlingame, Calif., USA). The FISH results 
were analyzed on a computer screen. Images of each of the 2 fluo-
rochromes were collected using an epifluorescence microscope 
(Leica DM, Rijswijk, The Netherlands) equipped with appropriate 
excitation and emission filter sets (Leica), and a cooled CCD cam-
era (Photometrics, Tucson, Ariz., USA). The green and blue im-
ages were collected sequentially by changing the excitation filter 
using CW4000 FISH software (Leica). Two investigators scored a 
minimum of 50 interphase cell nuclei per tissue core, and the 
number of green fluorescent centromere 1 spots per nucleus was 
scored (0, 1, 2, 3, 4,  1 4 spots/nuclear slice). Then, the percentage 
of hyperdiploid cell nuclei was determined.
 Immunohistochemistry p16, p53, Rb1 and Ki67 Antigen 
 The immunohistochemistry was carried out as described be-
fore by us  [13] . Basically, 4-  m consecutive tissue sections of the 
TMA were mounted on AAS-coated slides (Starfrost, Berlin, Ger-
many), and immunostaining was performed using the UltraVi-
sion Large Volume Detection System Anti-Polyvalent, HRP (Lab-
vision, Fremont, Calif., USA). After deparaffinization, microwave 
(700 W) pretreatment was performed for 15 min using citrate
buffer (10 m M citric acid monohydrate, pH 6.0). The p16 gene 
product was evaluated using antibody E6H4 (DAKO, Glostrup, 
Denmark), diluted 1/25 in phosphate-buffered saline/5% bovine 
serum albumin (BSA). To assess overexpression of the p53 pro-
tein, the primary antibody DO-7, recognizing both wild-type and 
mutant p53, (DAKO) was used, diluted 1/50 in phosphate-buff-
ered saline/5% BSA. The retinoblastoma gene product was evalu-
ated with clone Rb1 (DAKO), diluted 1/25 in phosphate-buffered 
saline/5% BSA. This antibody reacts with the cell cycle-related 
phosphorylated form of Rb protein. To estimate proliferation rate, 
primary labeling of the Ki67 antigen was performed with anti-
body Mib-1 (Immunotech, Marseille, France), diluted 1/100 in 
phosphate buffered saline (PBS)/5% BSA. As a positive control, a 
cytokeratin 8/18 antibody was used; as a negative control, the pri-
mary antibody was omitted. At least 50 cells were scored by two 
independent investigators. For Ki67, a percentage  1 1% was re-
garded as increased proliferation. For p16, p53 and Rb1, an identi-
cal scoring system was used: a percentage exceeding 1% of positive 
cells was regarded as protein overexpression of these tumor sup-
pressor genes. The cut-off value of 1% was based on immuno-
staining profiles of normal liver controls.
 SS-R Immunohistochemistry 
 Five-  m sections of the TMA were mounted on AAS-coated 
slides (Starfrost, Berlin, Germany). Immunohistochemistry was 
performed as described previously  [14] . Briefly, the slides were 
deparaffinized, dehydrated, exposed to microwave heating (in 
citric acid buffer, 10 min at 100 ° C), rinsed in tap water and PBS 
and incubated for 15 min in normal goat serum (1: 10 dilution in 
PBS + 5% BSA). Thereafter, the cells were incubated overnight at 
4 ° C with antibody against sst2A (SS-800 antibody, Biotrend, Co-
logne, Germany). The primary antibody was used at a dilution of 
1: 2,000 in PBS + 5% BSA. A standard streptavidin-biotinylated-
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peroxidase complex (ABC) kit (Biogenix, San Ramon, Calif., 
USA) was used according to the manufacturers protocol to visual-
ize the bound antibodies. Paraffin-embedded sections of normal 
human pancreas served as a positive control. Negative controls for 
immunohistochemistry included: (1) omission of the primary an-
tibody, (2) preabsorption of the antibodies with immunizing pep-
tide (at a concentration of 100 n M ). A tissue was considered posi-
tive for sst2A when immunostaining was abolished by preabsorp-
tion with the immunizing peptide. Specificity of the SS-800 sst2A 
antibody has been previously described in detail  [15] .
 Statistical Evaluation 
 The Mann-Whitney U test was used for comparisons between 
the specimen groups for the percentage of hyperdiploid cell nuclei 
(aneuploidy). It was further used to evaluate the clinical param-
eter age and tumor size. Fisher’s exact test was applied for com-
parisons of the immunostaining results between groups, as well 
as tumor grade in relation to FISH and immunostaining. Also the 
parameter gender was evaluated using this test. A p value of 0.05 
(two sided) was taken as the limit of significance. A p value be-
tween 0.05 and 0.10 was considered a statistical trend.
 Results 
 Patient Characteristics 
 Twenty-eight men and 17 women were investigated 
with a median age of 57 years (23–74) and a median tu-
mor size of 5 cm  [1–16] . Twenty-nine patients (64%) had 
underlying liver cirrhosis.
 Somatostatin Receptor 2 Expression 
 Somatostatin receptor 2 expression was assessed by 
immunohistochemistry. In our series of 45 tumors, sst2 
expression was detected in 30 tumors (67%). Patient and 
tumor characteristics compared with sst2 status of the 
tumor are summarized in  table 1 . Age, gender, tumor 
size, tumor grade and underlying liver disease of the 
sst2+ tumors were not significantly different from the 
sst2– tumors.
 Genetic Alterations 
 Protein (over)expression of tumor suppressor genes 
(p16, p53 and Rb1) was examined by immunohisto-
chemistry. The proliferative capacity was examined by 
immunostaining of Ki67 and DNA ploidy status (aneu-
ploidy) was measured by FISH with a chromosome 1-
specific repetitive DNA probe. The results are shown in 
 table 2 .
 Aneuploidy, i.e. the percentage of hyperdiploid cells, 
was 33 (range 8–70) in the ssr2+ tumors versus 19 (range 
10–66) in the sst2– tumors (NS). No differences were ob-
served between the sst2– and sst2+ tumors for p53, p16, 
Rb1 oncoprotein or proliferation markers.
sst2+ sst2– Total Difference
Patients 30 (67) 15 (33) 45 (100)
Age, years 59 (23–74) 53 (39–74) 57 (23–74) NS
Male 19 (63) 9 (60) 28 (62) NS
Female 11 (37) 6 (40) 17 (38)
Tumor diameter, cm 5 (1–16) 4 (2–12) 5 (1–16) NS
Grade I or II tumor 19 (63) 9 (60) 28 (62) NS
Grade III tumor 11 (37) 6 (40) 17 (38)
Underlying liver cirrhosis 20 (67) 9 (60) 29 (64) NS
Without liver cirrhosis 10 (33) 6 (40) 16 (36)
Figures in parentheses represent percentages or range.
Table 2. Genetic alterations in 45 HCCs in relation to sst2 expres-
sion
sst2+ sst2– Total Difference
Patients 30 (67) 15 (33) 45
P16+ 6 (20) 2 (13) 8 (18) NS
P16– 24 (80) 13 (87) 37 (82)
P53+ 15 (50) 8 (53) 23 (51) NS
P53– 15 (50) 7 (47) 22 (49)
Rb1+ 15 (50) 8 (53) 23 (51) NS
Rb 1– 15 (50) 7 (47) 22 (49)
Ki67+ 17 (57) 9 (60) 26 (58) NS
Ki 67– 13 (43) 6 (40) 19 (42)
Aneuploidy 33 (8–70) 19 (10–66) 28 (8–70) NS
Figures in parentheses represent percentages or range.
Table 1. Clinical and pathological data 
from 45 patients with HCC
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 Discussion 
 In preclinical studies, somatostatin analogues (SS) 
inhibit the growth of a wide variety of tumors in vivo 
and in vitro  [16–18] . The published studies regarding 
the efficacy of SS on survival in patients with HCC are 
conflicting. Some studies did not display an improve-
ment in survival in patients with unresectable HCCs 
 [4–6] , while others found a significant survival benefit 
 [7, 8, 19] . The placebo-controlled randomized trials did 
not show significant benefit of SS on patient survival 
 [4, 20] .
 There is no explanation for these contradictory re-
sults. If one analyzes the number of studies regarding the 
efficacy of SS in the treatment of HCC, it is striking that 
studies investigating the SS-R in human HCC are limit-
ed. The variations in receptor expression may explain 
differences in clinical efficacy. To our knowledge, 3 stud-
ies described the expression of tumor ssr in patients with 
HCC ( table 3 ). The studies of Bläker et al.  [21] and Reubi 
et al.  [22] studied the correlation between SS-Rs and tu-
mor characteristics. Our study confirmed their results 
that there is no correlation between tumor stage, tumor 
differentiation and underlying liver disease. Moreover, 
there was no correlation between SS-Rs and age or gen-
der. Therefore, it is not possible to predict the existence 
of SS-Rs in human HCC based on available clinical pa-
rameters. If the expression of SS-Rs in HCC plays a role 
in the outcome regarding SS treatment in patients with 
HCC, it is not possible to stratify the patients based on 
clinical characteristics.
 It is known that there are 5 subtypes of SS-Rs. All SS-
Rs  [1–5] have been implicated in antiproliferative signal-
ing  [23] . Our study investigated the ssr2 and not the oth-
er subtypes SS-Rs 1, 3–5. There is a difference in binding 
affinity between analogues of SS and the SS-Rs subtypes. 
Octreotide, an often used SS analogue, has a high binding 
affinity with sst2 compared to the other SS-R subtypes. 
The absence or presence of sst2 subtype in HCC might be 
the cause of the divergent biological responses in trials 
with octreotide in patients with advanced HCC. This is 
one of the reasons we tested sst2 in human HCC. The 
most important decisive factor to test sst2 is the fact that 
we examined the determination of SS-Rs subtypes with 
immunohistochemistry followed by a determination 
with PCR as the gold standard. The most reliable subtype 
determination was sst2 and sst3 (100% score). Testing for 
the other subtypes is in our hands not reproducible. Be-
cause of the high affinity with SS analogues, we deter-
mined that sst2 is the most clinical significant subtype. 
In our series, 67% of the HCCs expressed sst2, which is 
exactly the same percentage of sst2 found in the study of 
Reynaert et al.  [24] and higher than the 41% Bläker et al. 
 [21] found. Because of the higher binding affinity of sst2 
to SS analogues compared to the other SS-Rs subtypes 
and the variable ssrt2 expression in HCC found in our 
study and others, clinical trials evaluating the treatment 
of SS analogues in patients with HCC, should take these 
findings into account.
 SS-Rs may play a role in the progression of cancers. 
Binding studies suggested that SS-Rs were preferentially 
expressed in well-differentiated compared to less differ-
entiated tumors  [25, 26] . In other words, SS-Rs may play 
a role in the differentiation in some cancers. Loss of SS-
Rs expression in tumor cells would confer a proliferative 
advantage to those cells and their progeny. In regard of 
this point genes of the SS-Rs can be regarded as tumor 
suppressor genes. This suggestion is supported by the 
observation that a point mutation in sst2 gene results in 
a proliferative advantage in small cell lung cancer cells in 
vitro  [27] . If SS-Rs can be regarded as tumor suppressor 
genes, it might be that SS-Rs+ subgroup is a distinct 
group of patients. Maybe specific genetic alterations are 
associated with SS-R-positive HCCs and this may be an-
other possible explanation for the conflicting results re-
garding the effect of SS analogues on survival in patients 
with HCC.
 The p53 oncosuppressor is the gene which has been 
found to be most frequently altered in human cancers. 
Moreover, it is the most commonly mutated gene in HCC 
 [28–31] . In a large study of Qin et al.  [31] , nuclear staining 
for p53 was found in 50.5% of the cases (112 of the 222 
cases). Some reports are indicating that p53 is an inde-
pendent prognostic marker regarding survival  [30, 31] . 
Among the known tumor suppressor genes, the inactiva-
tion of p16 is reported to be second only to p53 inactiva-
tion in human neoplasia  [32] . Also in human HCC, p16 
Table 3. Somatostatin receptors in patients with HCC
Pa-
tients
SST2+
(tumor), %
Method
Reubi et al. [22] 59 411 autoradiography
Bläker et al. [21] 56 41 immunohistochemistry
Reynaert et al. [24] 6 67 immunohistochemistry
Erasmus M.C. 45 67 immunohistochemistry
1 All ssr subtypes (1–5).
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is a major inactivation target  [33, 34] . Edamoto et al. [35] 
recently demonstrated that alterations in the RB1 path-
ways commonly occur in HCCs. In a selected group of 45 
patients, we investigated whether any of the genetic al-
terations that are frequently observed in HCCs (p53, p16 
and RB1) were specific for the SS-R+ or SS-R– subgroups. 
None of the investigated oncogenes are specific for the 
subgroups.
 Conclusion 
 In 67% of the patients with HCC, sst2 could be detect-
ed in the tumor. No clinical characteristics were specific 
for sst2+ or sst2– tumors. There are no specific genetic 
alterations, aneuploidy or proliferation markers associ-
ated with sst2+ or sst2– HCCs.
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